A matter of choice? Patient decision-making and support in non-euploid embryo transfers. Viñals Gonzalez X, Akompey K, Sen Gupta S, Nicholls J. Human Fertility 2024;27(1):2431118.
People were recruited through a single online mosaic-embryo support group. Most were White, university-educated and treated in the USA. The results show patterns in these experiences, not how every patient feels.
Two terms worth knowing
What is PGT-A?
A few cells are taken from the embryo and checked for chromosome numbers. Think of your genetic material as books on a shelf: PGT-A doesn’t read the books for typos, it just counts them.
What is mosaicism?
Some of the embryo’s cells are normal and some are not, all in the same embryo.
Illustration only. Green cells are normal, terracotta cells are not.
What people told us
Many people ended up researching alone, using medical papers, peers, private genetic counsellors and social media groups. Some had to push their clinic to transfer a mosaic embryo, and described the emotional toll.
I wish PGT-A was explained as not an exact science.Participant #8
Questions to ask your clinic
Ask explicitly
- Does my clinic report mosaicism?
- What does it mean for my embryo?
- What are the risks and success rates?
Add outside support
Genetic counselling, peer-reviewed publications and reliable charities can fill gaps in what your clinic tells you.
Consider a second opinion
If your care team is reluctant to discuss or transfer mosaic embryos, a second view may help. Ask yourself whether the clinic invited your questions.
What was discussed before PGT-A
Share of respondents who recalled each topic being covered by their clinic.
What predicted feeling supported
Share who felt supported, by whether the topic was discussed (or by country).
All differences shown were significant (p < 0.01). Logistic regression: opportunity to discuss implications OR 3.98 for feeling empowered; USA OR 0.218 for feeling informed; AUC 0.755.
Three themes in the open-text answers
Mismatched expectations
PGT-A was presented as more certain than it is. Some did not know it is not diagnostic or that mosaic results were possible.
“Just thought it was to sort good from bad.” #46
Inadequate information
Outcomes after transfer, mosaic categories, incidence and success rates went unaddressed. People educated themselves.
“The info was bad… I had to educate myself.” #9
An unsupported decision
Some had to self-advocate to secure a transfer, and some felt pressured to test.
“I stopped all IVF because of the trauma of having to fight to use my mosaics.” #54
What happened to those who transferred
High-level mosaics did worse than low-level (clinical 87.5% vs 96%, ongoing 75% vs 91%), but the difference was not significant. A further 22 outcomes were pending. Of 43 yet to transfer, 58% planned to, 21% hoped to find a euploid embryo first, 14% were undecided and 7% gave other reasons. These are small, self-reported numbers, so treat them as description rather than evidence of effect.
What the authors recommend
For clinics
Put clinic policies on mosaic transfer into the consent form, and adopt the ESHRE recommendations.
For counselling
Offer standardised pre-test and post-test counselling by genetic counsellors or well-informed embryologists, plus psychological support.
Limits the authors note: only 0.8% of the group’s roughly 17,000 members responded (135), most respondents were White, educated and US-based, and treatment dates spanned 2016–2023, a period of rapid change. Source: Viñals Gonzalez et al., Hum Fertil 2024, doi:10.1080/14647273.2024.2431118. Casa Origen summarises research for information only; this is not medical advice.